Publicaciones › Edema macular diabético y sus tratamientos
Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mg
Triamcinolona acetonida intravítrea para edema macular diabético difuso: Ensayo de fase 2 comparando 4 mg vs 2 mg
| Año | 2006 |
|---|---|
| Fuente | American journal of ophthalmology |
| Tipo | article · Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial |
| Autores (8) | François Audren, Amélie Lecleire-Collet, Ali Erginay, Belkacem Haouchine, Rym Benosman, Jean-François Bergmann, Alain Gaudric, Pascale Massin |
| Posición de Erginay | 3 de 8 |
| Citas | 97 (OpenAlex) |
| Enlaces | DOI 10.1016/j.ajo.2006.06.011 · PubMed 16978576 · OpenAlex |
| Líneas | Edema macular diabético y sus tratamientos Enfermedades vasculares, genéticas e inflamatorias de la retina Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió la efectividad y seguridad de dos dosis de triamcinolona acetonida para tratar el edema macular diabético. Los pacientes recibieron una inyección intravítrea de 4 mg o 2 mg y se midió el grosor de la mácula y la agudeza visual. No se encontraron diferencias significativas entre las dos dosis en cuanto a grosor de la mácula, agudeza visual o presión intraocular.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
To prospectively compare the efficacy and safety of 4 vs 2 mg intravitreal triamcinolone acetonide (TA) injection for diabetic macular edema. Interventional case series. Thirty-two patients with diabetic macular edema unresponsive to laser photocoagulation. Patients were randomly assigned to receive 4 or 2 mg intravitreal TA in one eye (16 patients in each group). The main outcome was central macular thickness (CMT) measured by optical coherence tomography (OCT) at four, 12, and 24 weeks. Secondary outcomes were gain in Early Treatment Diabetic Retinopathy Study (ETDRS) scores, intraocular pressure (IOP), cataract progression, and duration of effect. Before injection, mean (+/- SD) CMT was 564.5 +/- 119 microm and 522.9 +/- 148.5 microm in the 4- and 2-mg groups, respectively. At four, 12, and 24 weeks after injection, it was 275.0 +/- 79.8, 271.4 +/- 128.7, and 448.7 +/- 146.4 microm, respectively, in the 4-mg group, and 267.3 +/- 82.4, 289.8 +/- 111.4, and 394.7 +/- 178.9 microm, respectively, in the 2-mg group. At no time was the difference in CMT between both groups statistically significant (P> 0.3). The between-group differences in the gain in the ETDRS score and in IOP were not statistically significant either. Diabetic macular edema recurred after a median period of 20 weeks vs 16 weeks in the 4- and 2-mg groups, respectively (P = 0.11). In the short term, intravitreal injection of 4 or 2 mg TA does not have different effects on CMT, visual acuity, or IOP.